Neurobehavioral syndrome induced by H2-receptor blocker withdrawal: Possible role of prolactin

Clinical Neuropharmacology

Volumn 20, Issue 1, 1997, Pages 49-54

  Rampello, Liborio ^a   Raffaele, Rocco ^a   Nicoletti, Giovanni ^a   Le Pira, Francesco ^a   Vecchio, Ignazio ^a   Malaguarnera, Mariano ^a   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

H2 Receptor blockers; Prolactin; Withdrawal syndrome

Indexed keywords

CIMETIDINE; DOMPERIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ADULT; AGITATION; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; HYPERPROLACTINEMIA; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RECEPTOR BLOCKING; STOMACH ACID SECRETION; STOMACH ULCER; WITHDRAWAL SYNDROME;

EID: 0031027640     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199702000-00006     Document Type: Article

References (16)

1. 2-reccptor antagonists in the short- and long-term treatment of duodenal ulcers. Clin Gastroenterol 1984;13:501-41.
2. Cantù TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991;114:1027-34.
3. Jensen RT, Collen MJ, Pandol SJ. Cimetidine induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983;308:883-7.
4. Francavilla A, Panella A, Ierardi E, et al. Effects of ranitidine: a short term clinical trial for duodenal ulcer treatment using two different types of oral administration: serum prolactin stimulation after bolus injection. Ital J Gastroenterol l983;15:39-43.
5. Drago F, van Ree JM, Bohus B, de Wied D. Endogenous hyperprolactinemia enhances amphetamine- and apomorphine-induced stereotypy. Eur J Pharmacol 1981;72:249-53.
6. Drago F, Bohus B, van Ree JM, Scapagnini U, de Wied D. Behavioral responses of long-term hyperprolactinemic rats. Eur J Pharmacol 1982;79:323-7.
7. Drago F. Behavioral effects of prolactin. Curr Top Neuroendocrinol 1990;10:263-89.
8. Creese J. Biochemical properties of CNS dopamine receptors. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press. 1987:257-64.
9. Agnoli A, Ruggieri S, Falaschi P, et al. Domperidone induced hyperprolactinemia improves clinical symptoms in Parkinson's disease: possible effect of prolactin at nigro-striatal level. In: MacLeod RM, ed. Central and peripheral regulation of prolactin function. New York: Raven Press, 1980:347-51.
10. Drago F, Gispen WH, Bohus B. Behavioral effects of prolactin: involvement of opioid receptors. In: Takagi H, Simon EJ, eds. Advances in endogenous and exogenous opioids. Tokyo: Kodansha, 1981:535-7.
11. Drago F, Scapagnini U. Effects of endogenous hyperprolactinemia on opiate-induced behavioral changes in rats. Brain Res 1985;336:215-21.
12. Drago F, Kovacs GL, Szabo G, Scapagnini U, Telegdy G. Effects of haloperidol on morphine-induced analgesia, morphine tolerance and withdrawal in hyperprolactinemic rats. Neuropharmacology 1985;24:1027-31.
13. Patti F, Drago F, Marano P, Nicoletti F, Scapagnini U. Effects of sulpiride on chronic abstinence syndrome in addicted patients. Clin Neuropharmacol 1986;9:469-76.
14. Rocco A, Mori F, Baldelli R, et al. Effect of chronic bromocriptine treatment on psychological profile of patients with PRL-secreting pituitary adenomas. Psychoneuroendocrinology 1993;18:57-66.
15. Pillai NP, Ramaswamy S, Gopalakrishnan V, Ghosh MN. Contractile effect of prolactin on guinea pig isolated ileum. Eur J Pharmacol 1981;72:11-6.
16. Oyewumi LK, Vollick D, Merskey H, Plumb C. Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci 1994;19:145-50.